Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gepaktiv vs UDCA and Ademetionine in MAFLD
NCT07068191Recruiting
- Sponsor
- Phenomen Pharma
- Start
- Jun 2025
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Randomised, open-label trial (3 arms), sponsored by Phenomen Pharma. Primary endpoints: Reduction in ALT levels by >=30% from baseline at 15 days, Change in liver size measured by ultrasound at 15 days and 2 more. Started Jun 2025; status: recruiting.
Beyond the preview
Go deeper on NCT07068191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07068191.